Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Nov 7;18(6):1429-1434.
doi: 10.5114/aoms/156147. eCollection 2022.

2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy

Maciej Banach  1   2   3 , Zeljko Reiner  4 , Arrigo F G Cicero  5   6 , Pierre Sabouret  7 , Margus Viigimaa  8   9 , Amirhossein Sahebkar  10   11   12   13 , Arman Postadzhiyan  14 , Dan Gaita  15   16 , Daniel Pella  17 , Peter E Penson  18   19
Affiliations
Editorial

2022: the year in cardiovascular disease - the year of upfront lipid lowering combination therapy

Maciej Banach et al. Arch Med Sci. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Maciej Banach: speakers bureau: Amgen, Daichii Sankyo, KRKA, Polpharma, Mylan/Viatris, Novartis, Novo-Nordisk, Sanofi-Aventis, Teva, Zentiva; consultant to Amgen, Daichii Sankyo, Esperion, NewAmsterdam, Novartis, Novo-Nordisk, Polfarmex, Sanofi-Aventis; Grants from Amgen, Daichii Sankyo, Mylan/Viatris, Sanofi and Valeant; Zeljko Reiner: speakers bureau: Sanofi, Novartis; Margus Viigimaa: speakers bureau: Amgen, Novartis, Novo-Nordisk, Sanofi-Aventis, Menarini; Arman Postadzhiyan: speakers bureau: Amgen, Novartis, Novo-Nordisk, Teva, Zentiva; Daniel Pella: received honoraria for events sponsored by Amgen, Jamieson, Novartis, MSD, Pfizer, Servier; Peter E. Penson owns four shares in AstraZeneca PLC and has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, Sanofi; all other authors have no conflict of interest.

Figures

Figure 1
Figure 1
How to be effective with lipid lowering therapy in ASCVD patients (the size of the LDL-C reduction for some recommended combinations is an assumption and still needs to be confirmed) *FDC of high intensity statin therapy and ezetimibe is a preferable option for all ASCVD patients. ASCVD – atherosclerotic cardiovascular disease, LDL-C – low-density lipoprotein cholesterol, ASC – acute coronary syndrome, PAD – peripheral artery disease, HIS – high intensity statin therapy, FDC – fixed dose combination, EZE – ezetimibe, BA – bempedoic acid, PCSK9i – proprotein convertase subtilisin/kexin 9 targeted approach therapy (PCSK9 inhibitors + inclisiran).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sabouret P, Angoulvant D, Cannon CP, Banach M. Low levels of low-density lipoprotein cholesterol, intracerebral haemorrhage, and other safety issues: is there still a matter of debate? Eur Heart J Open 2022; 2: oeac038. - PMC - PubMed
    1. Ray KK, Molemans B, Schoonen WM, et al.; DA VINCI study . EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol 2021; 28: 1279-89. - PubMed
    1. Vrablik M, Seifert B, Parkhomenko A, et al. Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study. Atherosclerosis 2021; 334: 66-75. - PubMed
    1. Lyall DM, Ward J, Banach M, et al. PCSK9 genetic variants and cognitive abilities: a large-scale Mendelian randomization study. Arch Med Sci 2021; 17: 241-4. - PMC - PubMed
    1. Banach M, López-Sendon JL, Averna M, et al. Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE. Arch Med Sci 2022; 18: 285-92. - PMC - PubMed

Publication types